Tag: FDA approves SKYRIZI
FDA Approves AbbVie’s SKYRIZI®️ for Pediatric Patients with Psoriatic Disease
AbbVie announced that the U.S. Food and Drug Administration (FDA) has approved SKYRIZI® (risankizumab-rzaa) for children aged six and older living with moderate-to-severe plaque...